{
    "name": "maralixibat",
    "comment": "Rx",
    "other_names": [
        "Livmarli"
    ],
    "classes": [
        "ASBT Inhibitors",
        "Ileal Bile Acid Transport Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/livmarli-maralixibat-4000208",
    "pregnancy": null,
    "lactation": null,
    "warnings": {
        "black_box_warning": {
            "common": [
                "Maternal use at the recommended dose is not expected to result in measurable fetal exposure owing to low systemic absorption following oral administration",
                "No developmental effects were observed in animal reproduction studies",
                "Low absorption following oral administration; breastfeeding is not expected to result in exposure to the infant at the recommended dose",
                "Data are not available on presence of drug in human milk, effects on breastfed infants, or effects on milk production",
                "As with pregnancy, consider supplementation with fat-soluble vitamins"
            ],
            "specific": [
                {
                    "type": "Clinical considerations",
                    "description": [
                        "Maralixibat may inhibit fat-soluble vitamin absorption",
                        "Monitor for deficiency and supplement as needed",
                        "Increased supplementation of vitamins may be needed during pregnancy"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Diarrhea, abdominal pain, and vomiting were reported as the most common adverse reactions; dosage interruption and/or discontinuation may be necessary"
            ],
            "specific": [
                {
                    "type": "Liver test abnormalities",
                    "description": [
                        "Patients with Alagille syndrome often present with jaundice or paucity of intrahepatic bile ducts",
                        "Obtain baseline liver tests and monitor during treatment",
                        "Consider dose reduction or treatment interruption if hepatic abnormalities occur in the absence of other causes",
                        "For persistent or recurrent liver test abnormalities, consider treatment discontinuation"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Bile acidâ€“resins",
                        "Administer maralixibat and bile acid binding resins 4 hr apart",
                        "Bile acid binding resins (eg, cholestyramine, colesevelam, colestipol) may bind to maralixibat in the gut",
                        "OATB2B1 substrates",
                        "Monitor effects of OATP2B1 substrates as needed",
                        "Maralixibat is an OATP2B1 inhibitor based on in vitro studies and may decrease oral absorption of OATP2B1 substrates (eg, statins) owing to OATP2B1 inhibition in the gastrointestinal tract",
                        "Fat-soluble vitamins",
                        "Monitor for vitamin deficiency and supplement as needed",
                        "Consider discontinuing maralixibat if deficiency persists or worsens despite adequate supplementation",
                        "Maralixibat may affect absorption of fat-soluble vitamins (eg, vitamins A, D, E, K); patients with Alagille syndrome can have fat-soluble vitamin deficiency at baseline"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "55.8"
        },
        {
            "name": "Abdominal pain",
            "percent": "53.5"
        },
        {
            "name": "Vomiting",
            "percent": "40.7"
        },
        {
            "name": "Fat",
            "percent": "25.6"
        },
        {
            "name": "soluble vitamin deficiency",
            "percent": "18.6"
        },
        {
            "name": "ALT",
            "percent": "10.4"
        },
        {
            "name": "AST increased",
            "percent": "9.3"
        },
        {
            "name": "Gastrointestinal bleeding",
            "percent": "8.1"
        },
        {
            "name": "Bone fractures",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        }
    ]
}